Tumor necrosis factor antagonists and their use in endometriosis

2004
Other OA: closed
⚙ AI-generated summary by qwen3.7-flash, 2026-09-26 ⓘ

This invention describes administering tumor necrosis factor antagonists, preferably soluble TNF receptors, to treat endometriosis by promoting the regression of endometriotic lesions and ameliorating related disorders such as infertility.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Tumor necrosis factor antagonists are administered in therapeutically effective doses to treat and/or prevent endometriosis. The antagonists of this invention typically are selected among various classes of molecules but preferably are soluble TNF receptors. The antagonists are useful for the regression of endometriotic lesions and, if combined with other active ingredients, for amelioration of related disorders, like infertility.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-15T06:08:49.021275+00:00